Can we count your visit with Google Analytics? No ads, no profiles. Details
HIMS
NYSENext earningsNov 9todayAnalystsHold13+20%Health Care · Health Care Technology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: vertically integrated DTC telehealth (web + app intake → async MD review → owned compounding pharmacy → recurring ship). ~2.4M subscribers, ~55% gross margin, accelerating personalization mix (multi-ingredient compounded SKUs lock in higher LTV than commodity finasteride/sildenafil).
GLP-1 leg added in 2025 via compounded semaglutide under the $LLY / $NVO shortage exemption, then transitioned toward branded supply + oral GLP-1 / liraglutide as the FDA shortage list cleared.
(1) subscription model with >85% gross retention and rising AOV as users stack categories; (2) weight-loss category opens a $10B+ TAM the legacy DTC men's/women's base could never reach; (3) owned pharmacy + 503B facility = structural cost advantage vs Ro / pure-marketplace peers; (4) brand + paid-acquisition flywheel already amortized - incremental subs come at lower CAC than 2023; (5) optionality on a personalized longevity / hormone bundle adjacent to peptide and TRT demand.
(1) compounded GLP-1 revenue is regulator-dependent - every FDA shortage update (semaglutide cleared Q1 2025) is a step-function risk to the highest-growth SKU; (2) $LLY and $NVO are actively building DTC channels ($LLY Direct) that disintermediate the compounded route; (3) gross margin compression as branded GLP-1 supply replaces in-house compounded; (4) heavy reliance on paid social CAC - TikTok / Meta cost inflation directly hits unit economics; (5) async-prescribing model faces ongoing state medical-board and DEA scrutiny on stimulants, GLP-1s, and controlled substances.
It reads our $HIMS data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Long-form analysis touching HIMS
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.